QualityStocksNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 HIV Monotherapy Trial Shows Promising Results
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning provided an update on its PRO 140 (leronlimab) as a single agent for maintenance of HIV viral load suppression. Per the update, approximately 92 percent of newly enrolled patients administered PRO 140 in a 700 mg dosage as part of the CD03 Phase 3 investigative monotherapy trial have achieved viral load suppression. Patients enrolled in the Phase 3 monotherapy trial were prescreened for CCR5-tropic HIV-1 infection and treated for up to 12 weeks. “Our analysis of data indicate that patients treated with PRO 140 700 mg dose who achieve suppressed viral load…